News & events

13th Tumour Models London Summit 2024, December 4-5, 2024

39th SITC meeting 2024, Houston, TX, November 6-10

ESMO (European Society For Medical Oncology) 2024, Barcelona, Spain, September 13-17, 2024

genOway Shanghai at the Chinese Biopharmaceutical Association meeting 2024

5th Annual STING & TLR-Targeted Therapies Summit, San Diego, CA, June 19-20, 2024

6th Annual Cell Engager Summit, Boston, MA, May 21-23, 2024

AACR Annual Meeting 2024, San Diego, CA, April 5-10

8th Annual Tumour Models, San Francisco, CA, Jan 30-Feb 01, 2024

Another technological achievement for genOway's humanized ICP (immune checkpoint) models, used successfully by Curadev Pharma in the preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers

Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance

genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology

ERS Genomics and genOway enter CRISPR/Cas9 agreement

After the United States, the European Patent Office delivers the first European patent for the SMASh technology — and genOway has acquired an exclusive license

genOway obtains €2,3M from the European Union and the Auvergne-Rhône-Alpes Region to develop humanized immune checkpoint models

genOway and Cyagen have joined forces to form a long-term strategic partnership in the Asia-Pacific region

genOway and Merck strengthen CRISPR/Cas9 strategic alliance by extending their partnership to all animal cell models

genOway announces the consolidation of a precompetitive consortium to develop and validate humanized immune checkpoint mouse models

genOway licenses the Flex technology rights to HHMI for the distribution of its AAV FLEX